Short Interest in Kiromic BioPharma, Inc. (NASDAQ:KRBP) Declines By 47.5%

Kiromic BioPharma, Inc. (NASDAQ:KRBPGet Rating) was the target of a large decrease in short interest in the month of April. As of April 30th, there was short interest totalling 95,400 shares, a decrease of 47.5% from the April 15th total of 181,700 shares. Based on an average daily volume of 312,300 shares, the days-to-cover ratio is currently 0.3 days.

Shares of KRBP opened at $0.38 on Friday. Kiromic BioPharma has a 52-week low of $0.30 and a 52-week high of $11.00. The company has a 50-day simple moving average of $0.74 and a 200-day simple moving average of $1.38.

Kiromic BioPharma (NASDAQ:KRBPGet Rating) last issued its earnings results on Friday, March 11th. The company reported ($0.40) earnings per share for the quarter. On average, equities research analysts forecast that Kiromic BioPharma will post -1.45 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KRBP. 1492 Capital Management LLC raised its position in Kiromic BioPharma by 21.3% during the third quarter. 1492 Capital Management LLC now owns 434,408 shares of the company’s stock worth $1,334,000 after acquiring an additional 76,402 shares during the last quarter. Intellectus Partners LLC lifted its stake in Kiromic BioPharma by 32.0% in the 3rd quarter. Intellectus Partners LLC now owns 98,850 shares of the company’s stock valued at $303,000 after buying an additional 23,950 shares in the last quarter. LPL Financial LLC grew its holdings in Kiromic BioPharma by 59.8% during the 4th quarter. LPL Financial LLC now owns 84,400 shares of the company’s stock valued at $129,000 after buying an additional 31,600 shares during the last quarter. Zeke Capital Advisors LLC increased its position in Kiromic BioPharma by 236.7% during the third quarter. Zeke Capital Advisors LLC now owns 56,899 shares of the company’s stock worth $175,000 after buying an additional 40,000 shares in the last quarter. Finally, Geode Capital Management LLC acquired a new position in shares of Kiromic BioPharma in the third quarter worth $158,000. 16.03% of the stock is owned by hedge funds and other institutional investors.

Kiromic BioPharma Company Profile (Get Rating)

Kiromic BioPharma, Inc, a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy.

See Also

Receive News & Ratings for Kiromic BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiromic BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.